Key Highlights

  • Second-quarter net sales rose about 28% year-over-year to roughly $9.5 million, driven by outsized growth in the Quell and Truvaga consumer neurostimulation lines.
  • Management raised full-year 2026 Revenue guidance to more than 30% growth and pointed to a path toward positive adjusted EBITDA.
  • GAAP net loss narrowed to $3.1 million, or $0.33 per share, from the prior-year period.
  • The company's trailing-twelve-month net loss totaled approximately $14.8 million, with cash and short-term investments of roughly $10 million against total Debt of around $9.6 million.

electroCore, Inc. (NASDAQ:ECOR), the bioelectronic medicine company behind the gammaCore vagus nerve stimulator and the consumer-facing Truvaga device, raised its full-year revenue guidance following strong second-quarter results.

The company's pivot from a single-product prescription device maker toward a broader bioelectronic medicine platform spanning clinical, veteran-focused, and consumer wellness channels continues to show results, with triple-digit percentage growth in Quell and steady scaling of Truvaga.

electroCore reported its second-quarter 2026 results on August 6, 2026, marking one of its most encouraging quarters in years.

Second-Quarter Results

The company posted second-quarter net sales of roughly $9.5 million, up about 28% year-over-year, and narrowed its GAAP net loss to $3.1 million, or $0.33 per share. Management reported strong momentum in its consumer wearables segment, with Quell sales reportedly surging on a percentage basis and Truvaga continuing to scale.

The company's legacy gammaCore prescription device maintained a steadier revenue base tied to migraine and cluster headache treatment, complementing the faster-growing consumer product lines.

Raised Guidance

Management raised full-year 2026 revenue guidance to more than 30% growth, alongside commentary about approaching positive adjusted EBITDA, signaling that the company's multi-year turnaround toward diversified, higher-margin consumer health products is gaining traction.

This raised outlook reflects growing confidence in the sustained growth trajectory of the Quell and Truvaga product lines as they continue to scale within the consumer wellness market.

Financial Position

On a trailing-twelve-month basis, revenue stood at roughly $37 million, up about a third from the prior year, while the net loss over that same period totaled approximately $14.8 million. Cash and short-term investments were reported at roughly $10 million against total debt of around $9.6 million.

Operating cash flow remained negative, at roughly $9.7 million over the trailing twelve months, underscoring that electroCore is still investing ahead of profitability even as its Top Line expands.

The Investment Case

The bull case for electroCore centers on its pivot toward a broader bioelectronic medicine platform, with triple-digit percentage growth in Quell and steady scaling of Truvaga suggesting the company may be finding real product-market fit in direct-to-consumer neurostimulation.

electroCore remains unprofitable and operates in a competitive neurostimulation and wellness-device landscape, meaning continued execution on both clinical and consumer channels will be important for sustaining the current growth trajectory.

What Comes Next

Shareholders should watch third-quarter 2026 results for confirmation that the Quell and Truvaga growth trends and improving loss trajectory continued. Progress toward the company's stated goal of positive adjusted EBITDA will be a key profitability milestone.

Any updates on Veterans Affairs channel opportunities, which management has flagged as a growth avenue, Warrant attention, as would any financing activity given the company's net cash position.

A Growth Story Backed by Raised Guidance

electroCore's strong second-quarter results and raised full-year guidance reflect genuine progress in the company's multi-year turnaround toward a diversified bioelectronic medicine platform.

The company's growth in consumer wearables and narrowing losses represent meaningful steps toward the stated goal of positive adjusted EBITDA, positioning electroCore for continued attention as it executes on its expanded product strategy.